Akèy › Gliyoblastòm › North Carolina › Durham
Etid klinik pou Gliyoblastòm nan Durham, NC
20 etid pou Gliyoblastòm ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Ap rekriteFaz 3
- University of North Carolina, Chapel Hill · 10 mi lwen
Targeted Pediatric High-Grade Glioma Therapy
Ap rekriteEtid obsèvasyon
- Duke University Health System, Durham
Study of Olutasidenib and Temozolomide in HGG
Ap rekriteFaz 2
- Duke University Health System, Durham
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Ap rekriteFaz 3
- Duke Cancer Institute, Durham
BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
Ap rekriteFaz 1
- Duke University Medical Center, Durham
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Ap rekriteFaz 2
- Duke University Medical Center, Durham
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Ap rekriteFaz 2
- Duke University, Durham
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Ap rekriteFaz 2
- Duke University, Durham
Lerapolturev (PVSRIPO) in GBM
Ap rekriteFaz 2
- Duke University Medical Center, Durham
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Ap rekriteFaz 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Ap rekriteFaz 1 bonèVolontè an sante akeyi
- Duke University Health System, Durham
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
Ap rekriteFaz 1
- Duke University Medical Center, Durham
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ap rekriteFaz 2
- Duke University Health System, Durham
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
Ap rekriteFaz 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Key Longitudinal Associations With Risk and Glioblastoma Outcomes
Ap rekriteEtid obsèvasyon
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi lwen
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
Ap rekriteFaz 1
- Duke University Medical Center, Durham
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Ap rekriteFaz 1/2
- Duke University Medical Center, Durham
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Ap rekriteFaz 1
- Duke University, Durham
Etid Gliyoblastòm nan lòt vil
- New York City, NY30 etid
- Boston, MA28 etid
- Houston, TX26 etid
- Los Angeles, CA24 etid
- San Francisco, CA17 etid
- Chicago, IL15 etid
- Washington, DC15 etid
- Columbus, OH14 etid
- Miami, FL14 etid
- Rochester, MN13 etid
- Jacksonville, FL13 etid
- Aurora, CO12 etid
Lòt etid nan Durham
- Kansè nan tete64 etid
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Leksemi mieloïd egi33 etid
- Kansè Metastatik33 etid
- Kansè pwostat32 etid
- Kansè poumon32 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Lukemi lenfositè kwonik27 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.